| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8227808 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 7 Pages |
Abstract
The MTD of vandetanib, with SRS in recurrent malignant glioma, is 100 mg daily. Further evaluation of safety and efficacy is warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Emma C. M.D., Denise M.D., Laurie E. M.D., M.B.A., Arthur K. M.D., Ph.D., Brian D. M.D., M.P.H., Allen M.D., Kevin M.D., Changhu M.D.,